NASDAQ:ICAD - iCAD Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $4.05 +0.10 (+2.53 %) (As of 12/11/2018 11:56 AM ET)Previous Close$3.95Today's Range$3.94 - $4.0652-Week Range$2.42 - $4.68Volume13,296 shsAverage Volume104,127 shsMarket Capitalization$64.91 millionP/E Ratio-6.64Dividend YieldN/ABeta0.9 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire. Receive ICAD News and Ratings via Email Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorComputer and Technology Current SymbolNASDAQ:ICAD Previous Symbol CUSIPN/A Webwww.icadmed.com Phone603-882-5200 Debt Debt-to-Equity Ratio0.49 Current Ratio1.39 Quick Ratio1.23 Price-To-Earnings Trailing P/E Ratio-6.64 Forward P/E Ratio-9.64 P/E GrowthN/A Sales & Book Value Annual Sales$28.10 million Price / Sales2.42 Cash FlowN/A Price / Cash FlowN/A Book Value$0.86 per share Price / Book4.71 Profitability EPS (Most Recent Fiscal Year)($0.61) Net Income$-14,250,000.00 Net Margins-37.29% Return on Equity-64.08% Return on Assets-25.38% Miscellaneous Employees119 Outstanding Shares16,770,000Market Cap$64.91 million OptionableOptionable iCAD (NASDAQ:ICAD) Frequently Asked Questions What is iCAD's stock symbol? iCAD trades on the NASDAQ under the ticker symbol "ICAD." How were iCAD's earnings last quarter? iCAD Inc (NASDAQ:ICAD) released its quarterly earnings data on Tuesday, November, 13th. The technology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. The technology company had revenue of $6.19 million for the quarter, compared to analysts' expectations of $6.34 million. iCAD had a negative net margin of 37.29% and a negative return on equity of 64.08%. View iCAD's Earnings History. When is iCAD's next earnings date? iCAD is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for iCAD. Has iCAD been receiving favorable news coverage? Media coverage about ICAD stock has trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. iCAD earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned news articles about the technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. Who are some of iCAD's key competitors? Some companies that are related to iCAD include Pulse Biosciences (PLSE), T2 Biosystems (TTOO), RenovaCare (RCAR), RA Medical Systems (RMED), Alphatec (ATEC), Sensus Healthcare (SRTS), Apollo Endosurgery (APEN), STRATA Skin Sciences (SSKN), Endologix (ELGX), Arch Therapeutics (ARTH), Invo Bioscience (IVOB), Pro-Dex (PDEX), CAS Medical Systems (CASM), Repro-Med Systems (REPR) and Motus GI (MOTS). Who are iCAD's key executives? iCAD's management team includes the folowing people: Mr. Kenneth M. Ferry, CEO & Director (Age 64)Mr. Richard C. Christopher, Exec. VP, CFO, Treasurer & Sec. (Age 48)Ms. Stacey M. Stevens, Exec. VP and Chief Strategy & Commercial Officer (Age 50)Ms. Annette L. Heroux, VP of Admin. (Age 61)Mr. Jonathan Go, Sr. VP of R&D (Age 55) Who are iCAD's major shareholders? iCAD's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (3.43%). View Institutional Ownership Trends for iCAD. Which major investors are buying iCAD stock? ICAD stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. View Insider Buying and Selling for iCAD. How do I buy shares of iCAD? Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is iCAD's stock price today? One share of ICAD stock can currently be purchased for approximately $4.00. How big of a company is iCAD? iCAD has a market capitalization of $64.91 million and generates $28.10 million in revenue each year. The technology company earns $-14,250,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. iCAD employs 119 workers across the globe. What is iCAD's official website? The official website for iCAD is http://www.icadmed.com. How can I contact iCAD? iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected] MarketBeat Community Rating for iCAD (NASDAQ ICAD)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 80 (Vote Outperform)Underperform Votes: 94 (Vote Underperform)Total Votes: 174MarketBeat's community ratings are surveys of what our community members think about iCAD and other stocks. Vote "Outperform" if you believe ICAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICAD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/11/2018 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio?